Video Player is loading.
Advertisement
Current Time 0:00
Duration -:-
Loaded: 0%
Stream Type LIVE
Remaining Time -:-
1x

    Up next


    Mass Vaccination in a Pandemic - Benefits versus Risks: Interview with Geert Vanden Bossche

    healthinformation
    healthinformation - 1,099 Views
    30
    1,099 Views
    Published on 16 Jul 2021 / In Health

    Highlighting the principle of using a prophylactic vaccine in the midst of a pandemic. Likely to create more more viral variants in the process.

    Timecodes:
    0:00 - Intro
    7:36 - Lockdowns
    8:51 - Gaining immunity from exposure & immunological escape
    11:17 - COVID vaccine
    18:30 - COVID antibodies
    19:55 - NK Cells
    25:00 - Antigen-specific antibodies outcompete natural antibodies
    28:51 - Highly-infectious strain
    31:01 - Vaccine resistance in COVID pandemic
    31:51 - More on immunological escape
    32:59 - Geert Vanden Bossche’s thoughts on COVID vaccination

    Geert Vanden Bossche PhD, is an internationally recognised vaccine developer having worked as the head of the Vaccine Development Office at the German Centre for Infection Research.

    Coordinated Global Alliance for Vaccines and Immunisation's Ebola Vaccine Program and contributed to the implementation of an integrated vaccine work plan in collaboration with Global Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA) and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine candidates.

    Sharing his perspective on mass vaccination in COVID-19.

    You can support us with a financial contribution through Patreon. Access to more posts, podcasts and videos.
    https://patreon.com/VejonHealth

    Learn more about autoimmunity in COVID-19.
    https://mcmillanresearch.com/

    Show more
    1 Comments sort Sort by

    AnonArrow2
    AnonArrow2 3 years ago

    Thank you for saving this video

    Reply   thumb_up 0   thumb_down 0
    Show more

    Up next